Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

Multiple myeloma (MM) is an incurable malignancy with an unmet need for innovative treatment options. Histone deacetylase inhibitors (HDACi) are a new class of anticancer agent that have demonstrated activity in hematological malignancies. Here, we investigated the efficacy and safety of HDACi (vori...

Descripción completa

Detalles Bibliográficos
Autores principales: Matthews, G M, Lefebure, M, Doyle, M A, Shortt, J, Ellul, J, Chesi, M, Banks, K-M, Vidacs, E, Faulkner, D, Atadja, P, Bergsagel, P L, Johnstone, R W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789166/
https://www.ncbi.nlm.nih.gov/pubmed/24030150
http://dx.doi.org/10.1038/cddis.2013.306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789166/
https://www.ncbi.nlm.nih.gov/pubmed/24030150
http://dx.doi.org/10.1038/cddis.2013.306

Ejemplares similares